Industry Reports
Questex Acquires ExL Events
Questex, a leading global business information and events company announced it has acquired ExL Events, Inc., expanding Questex's presence in the global pharmaceutical, life...
Press Releases
EC Grants Marketing Authorization for Gilead’s Epclusa for the Treatment of All Genotypes of Chronic Hepatitis C
Gilead Sciences, Inc announced that the European Commission has granted marketing authorization for Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), the first pan-genotypic, single tablet...
Press Releases
Sanofi and WRAIR sign research agreement to co-develop Zika vaccine candidate
Sanofi and its vaccines global business unit Sanofi Pasteur Research and Development Agreement with the Walter Reed Army Institute of Research (WRAIR) on the...
Industry Reports
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Bristol-Myers Squibb Company and Cormorant Pharmaceuticals announced that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm, Sweden-based...
Press Releases
FDA Approves Gilead’s Epclusa for the Treatment of All Genotypes of Chronic Hepatitis C
Gilead Sciences, Inc. announced that the U.S. FDA has approved Epclusa , the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults...
Press Releases
Merck, Premier Inc collaborate to improve care for osteoporosis patients
Merck and Premier Inc , a leading healthcare improvement company, have agreed to collaborate on the co-development of solutions to help improve population health....
News
GSK start of phase- I oncology study with its ICOS agonist antibody
GSK announced the start of a phase I clinical trial with GSK3359609, an investigational inducibile T-cell costimulator (ICOS) agonist antibody. ICOS is a co-stimulatory...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read